The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine — the nation's only traditional ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...

Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

WASHINGTON — Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the ...

Per the Post, which first reported the story, “‘All new vaccines will undergo safety testing in placebo-controlled trials ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

The anticipated rollout of updated Covid vaccines this fall might be at risk after a change by Health and Human Services ...

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...

A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...

In the most recent trading session, Novavax (NVAX) closed at $6.41, indicating no shift from the previous trading day.